{"id":53110,"date":"2023-09-20T09:42:40","date_gmt":"2023-09-20T09:42:40","guid":{"rendered":"https:\/\/medsname.com\/anabrez\/"},"modified":"2026-04-30T16:30:24","modified_gmt":"2026-04-30T16:30:24","slug":"anabrez","status":"publish","type":"product","link":"https:\/\/medsbase.com\/ro\/product\/anabrez\/","title":{"rendered":"Anabrez"},"content":{"rendered":"<div class=\"medsbase-tldr-answer\" style=\"background:#fff8e1;border-left:4px solid #f5a623;padding:14px 18px;margin:18px 0;border-radius:4px;\">\n<h3 style=\"margin-top:0;\">R\u0103spuns rapid<\/h3>\n<p style=\"margin-bottom:0;\"><strong>Anabrez<\/strong> \u2014 Anastrozol 1 mg (produc\u0103tor certificat WHO-GMP). Inhibitor de aromataz\u0103 pentru cancerul mamar cu receptori hormonali pozitivi (HR+) la femeile postmenopauzale \u2014 \u00een regim adjuvant, adjuvant extins \u0219i metastatic. Administrare oral\u0103 o dat\u0103 pe zi.<\/p>\n<\/div>\n<div class=\"medsbase-trust-strip\" style=\"background:#f7f7f7;border-left:4px solid #2c7cb0;padding:14px 18px;margin:18px 0;border-radius:4px;\">\n<p style=\"margin:0 0 6px 0;\"><strong>Ce beneficii ofer\u0103 MedsBase:<\/strong><\/p>\n<ul style=\"margin:6px 0 0 22px;padding:0;list-style:disc;\">\n<li>produc\u0103tor certificat WHO-GMP<\/li>\n<li>Ambalaj discret \u00een plic simplu<\/li>\n<li>Livrare \u00een toat\u0103 lumea<\/li>\n<li>Evaluat de peste 1.400 de clien\u021bi (<a href=\"https:\/\/medsbase.com\/ro\/reviews\/\">cite\u0219te recenziile<\/a>)<\/li>\n<\/ul>\n<\/div>\n<p class=\"medsbase-reship-line\" style=\"background:#eef7ee;border-left:4px solid #4caf50;padding:10px 14px;margin:14px 0;border-radius:3px;\">\ud83d\udce6 <strong>Garan\u021bia de retransmitere:<\/strong> dac\u0103 comanda dvs. nu a ajuns \u00een 20 de zile lucr\u0103toare de la expediere, o retransmitem f\u0103r\u0103 costuri suplimentare. <a href=\"https:\/\/medsbase.com\/ro\/medsbase-re-shipment-assurance-policy\/\">Cite\u0219te politica<\/a>.<\/p>\n<h3>De ce s\u0103 comanzi de la MedsBase<\/h3>\n<p>Anabrez este expediat de la un produc\u0103tor certificat WHO-GMP \u00een ambalaj simplu, facturat printr-un procesor de plat\u0103 reglementat (descrierea extrasului de cont indic\u0103 un procesor de plat\u0103 cu card reglementat \u2014 niciodat\u0103 MedsBase sau nume de medicament). Fiecare comand\u0103 beneficiaz\u0103 de Asigurarea noastr\u0103 de Retrimitere \u00een 20 de zile lucr\u0103toare.<\/p>\n<div class=\"medsbase-specialist-strip\" style=\"background:#fff3f3;border-left:4px solid #d9534f;padding:14px 18px;margin:18px 0;border-radius:4px;\">\n<p style=\"margin:0;\"><strong>\u26a0\ufe0f Terapie oncologic\u0103 supravegheat\u0103 de specialist<\/strong> \u2014 acest medicament este ini\u021biat, monitorizat \u0219i \u00eentrerupt de un oncolog sau hematolog. Dozarea depinde de tipul tumorii, stadiul, suprafa\u021ba corporal\u0103, func\u021bia organelor \u0219i terapia concomitant\u0103. Autotratamentul nu este adecvat; informa\u021biile de mai jos au scop educa\u021bional \u0219i sus\u021bin conversa\u021biile informate cu specialistul dumneavoastr\u0103.<\/p>\n<\/div>\n<div style=\"background:#fff3f3;border-left:4px solid #d9534f;padding:12px 16px;margin:14px 0;border-radius:3px;\"><strong>Doar postmenopauz\u0103<\/strong><br \/>Inhibitorii de aromataz\u0103 (AI) NU sunt eficien\u021bi la femeile premenopauzale \u2014 f\u0103r\u0103 suprimarea ovarian\u0103, ovarele dep\u0103\u0219esc inhibi\u021bia AI. Cancerul de s\u00e2n HR+ la femeile premenopauzale necesit\u0103 tamoxifen \u00b1 suprimare ovarian\u0103 (agonist LHRH) sau AI CU suprimare ovarian\u0103 ca regim supravegheat de specialist.<\/div>\n<div style=\"background:#fff3f3;border-left:4px solid #d9534f;padding:12px 16px;margin:14px 0;border-radius:3px;\"><strong>Pierdere densitate osoas\u0103 + risc cardiovascular<\/strong><br \/>Inhibitorii de aromataz\u0103 accelereaz\u0103 pierderea densit\u0103\u021bii osoase \u0219i riscul de fractur\u0103. Se recomand\u0103 evaluare DEXA ini\u021bial\u0103; lua\u021bi \u00een considerare bisfosfonat (acid zoledronic, ibandronat) sau denosumab \u00een osteopenie\/osteoporoz\u0103. AI pot cre\u0219te u\u0219or nivelurile de lipide \u0219i evenimentele cardiovasculare comparativ cu tamoxifen. Monitoriza\u021bi lipidele \u0219i factorii de risc cardiovascular anual.<\/div>\n<h2 id=\"faqs\">\u00centreb\u0103ri frecvente<\/h2>\n<h3>AI vs tamoxifen \u2014 care este mai bun?<\/h3>\n<p>\u00cen cancerul de s\u00e2n HR+ postmenopauzal, inhibitorii de aromataz\u0103 (anastrozol, letrozol, exemestan) ofer\u0103 o supravie\u021buire f\u0103r\u0103 boal\u0103 u\u0219or mai mare dec\u00e2t tamoxifen (ATAC, BIG 1-98, MA.17). AI sunt prefera\u021bi ca tratament adjuvant la majoritatea femeilor postmenopauzale; tamoxifen r\u0103m\u00e2ne preferat \u00een boala premenopauzal\u0103 \u0219i la pacien\u021bii cu efecte adverse severe la AI.<\/p>\n<h3>C\u00e2t dureaz\u0103 tratamentul?<\/h3>\n<p>Terapia adjuvant\u0103 dureaz\u0103 de obicei 5 ani; unele femei beneficiaz\u0103 de terapie adjuvant\u0103 extins\u0103 (5-10 ani \u00een total) pe baza datelor ATLAS\/MA.17. Specialistul decide terapia extins\u0103 \u00een func\u021bie de riscul de recidiv\u0103.<\/p>\n<h3>Efecte secundare frecvente?<\/h3>\n<p>V\u0103rs\u0103turi de c\u0103ldur\u0103, dureri articulare \u0219i musculare (artralgie\/mialgie \u2014 afecteaz\u0103 30-50%, deseori se \u00eembun\u0103t\u0103\u021be\u0219te cu continuarea terapiei), oboseal\u0103, uscare vaginal\u0103, modific\u0103ri de stare, pierdere accelerat\u0103 de densitate osoas\u0103.<\/p>\n<h3>Durere articular\u0103 \u2014 este grav\u0103?<\/h3>\n<p>Artralgia legat\u0103 de AI este cel mai frecvent motiv pentru neconformitate. Se \u00eembun\u0103t\u0103\u021be\u0219te deseori \u00een 3-6 luni; ameliorare simptomatic\u0103 cu AINS, exerci\u021bii, ocazional schimbarea \u00eentre AI (anastrozol \u2194 letrozol \u2194 exemestan). Niveluri adecvate de vitamina D + calciu ajut\u0103.<\/p>\n<h3>Ce se \u00eent\u00e2mpl\u0103 dac\u0103 sunt \u00een premenopauz\u0103?<\/h3>\n<p>AI singuri nu func\u021bioneaz\u0103 \u2014 ovarele contracareaz\u0103. Discuta\u021bi tamoxifen, sau AI + suprima\u021bie ovarian\u0103, cu specialistul dumneavoastr\u0103.<\/p>\n<h3>Densitatea osoas\u0103?<\/h3>\n<p>DEXA de baz\u0103 obligatorie. Repeta\u021bi la fiecare 1-2 ani. Ad\u0103uga\u021bi un bisfosfonat sau denosumab dac\u0103 apare osteopenie sau osteoporoz\u0103, sau la pacien\u021bi cu risc ridicat de baz\u0103 profilactic.<\/p>\n<h3>Efecte secundare vs exemestan?<\/h3>\n<p>Anastrozolul \u0219i letrozolul sunt AI nesteroidieni (reversibili). Exemestanul este un AI steroidian (inactivator ireversibil). Profilele de efecte secundare sunt \u00een general similare; unele femei prefer\u0103 unul fa\u021b\u0103 de altul. Schimbarea este rezonabil\u0103 pentru tolerabilitate.<\/p>\n<h3>Uscare vaginal\u0103?<\/h3>\n<p>Comun\u0103. Emolien\u021bi vaginali topici \u0219i lubrifian\u021bi pe baz\u0103 de ap\u0103 ajut\u0103. Estrogenul topic (doz\u0103 foarte mic\u0103, vaginal) este \u00een general evitat \u00een cancerul de s\u00e2n HR+; dac\u0103 simptomele sunt severe, discuta\u021bi cu oncologul \u2014 DHEA vaginal, ospemifen, sau evaluare specializat\u0103 de menopauz\u0103 pot fi op\u021biuni.<\/p>\n<h3>Interac\u021biuni medicamentoase?<\/h3>\n<p>Pu\u021bine majore. Modulatorii CYP au efect minimal asupra AI. Tamoxifenul \u0219i AI NU trebuie combina\u021bi (niciun beneficiu). Dezv\u0103lui\u021bi \u00eentotdeauna toate medicamentele.<\/p>\n<h3>Ce fac dac\u0103 uit o doz\u0103?<\/h3>\n<p>Lua\u021bi c\u00e2nd v\u0103 aminti\u021bi dac\u0103 \u00een aceea\u0219i zi; altfel omite\u021bi. Nu dubla\u021bi doza. Dozarea zilnic\u0103 consistent\u0103 maximizeaz\u0103 efectul.<\/p>\n<p><!-- medsbase-related-alts-v1 --><\/p>\n<h2>Alte Medicamente pentru Cancer \u0219i Terapie Hormonal\u0103<\/h2>\n<ul>\n<li><a href=\"https:\/\/medsbase.com\/ro\/xeloda\/\">Xeloda<\/a> \u2014 capecitabin\u0103 500 mg \u2014 prodrog oral de 5-FU pentru cancerul de s\u00e2n\/colorectal\/gastric<\/li>\n<li><a href=\"https:\/\/medsbase.com\/ro\/altraz\/\">Altraz<\/a> \u2014 anastrozol 1 mg \u2014 inhibitor de aromataz\u0103 pentru cancerul de s\u00e2n la femei postmenopauzale<\/li>\n<li><a href=\"https:\/\/medsbase.com\/ro\/xbira\/\">Xbira<\/a> \u2014 abirateron\u0103 250 mg \u2014 inhibitor CYP17 pentru cancerul metastatic de prostat\u0103<\/li>\n<li><a href=\"https:\/\/medsbase.com\/ro\/zoldria\/\">Zoldria<\/a> \u2014 acid zoledronic IV \u2014 pentru metastaze osoase \u0219i hipercalcemie<\/li>\n<li><a href=\"https:\/\/medsbase.com\/ro\/actorise\/\">Actorise<\/a> \u2014 darbepoetin alfa \u2014 pentru anemie indus\u0103 de chimioterapie<\/li>\n<\/ul>\n<div style=\"background:#fff3f3;border-left:4px solid #d9534f;padding:12px 16px;margin:18px 0;border-radius:3px;font-size:.95em;\"><strong>Disclaimer medical:<\/strong> Tratamentul cancerului este foarte individualizat. Medicamentul specific, doza, programul, monitorizarea \u0219i \u00eengrijirea de sus\u021binere trebuie stabilite de un oncolog sau hematolog calificat, pe baza biologiei tumorii, stadializ\u0103rii, comorbidit\u0103\u021bilor \u0219i obiectivelor terapiei. Aceast\u0103 informa\u021bie are caracter educa\u021bional; nu \u00eenlocuie\u0219te sfatul medical profesionist.<\/div>","protected":false},"excerpt":{"rendered":"<p>Anabrez (Anastrozol 1 mg) \u2014 inhibitor de aromataz\u0103 pentru cancerul mamar HR-pozitiv adjuvant \u0219i metastatic la femeile postmenopauzale. Terapie oral\u0103 o dat\u0103 pe zi, supravegheat\u0103 de specialist.<\/p>","protected":false},"featured_media":53111,"comment_status":"open","ping_status":"open","template":"","meta":[],"product_brand":[],"product_cat":[3595,3141,3223],"product_tag":[],"class_list":{"0":"post-53110","1":"product","2":"type-product","3":"status-publish","4":"has-post-thumbnail","6":"product_cat-anti-cancer-medication","7":"product_cat-category-overview","8":"product_cat-chronic-conditions","10":"first","11":"outofstock","12":"shipping-taxable","13":"purchasable","14":"product-type-variable","15":"has-default-attributes"},"acf":[],"_links":{"self":[{"href":"https:\/\/medsbase.com\/ro\/wp-json\/wp\/v2\/product\/53110","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/medsbase.com\/ro\/wp-json\/wp\/v2\/product"}],"about":[{"href":"https:\/\/medsbase.com\/ro\/wp-json\/wp\/v2\/types\/product"}],"replies":[{"embeddable":true,"href":"https:\/\/medsbase.com\/ro\/wp-json\/wp\/v2\/comments?post=53110"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/medsbase.com\/ro\/wp-json\/wp\/v2\/media\/53111"}],"wp:attachment":[{"href":"https:\/\/medsbase.com\/ro\/wp-json\/wp\/v2\/media?parent=53110"}],"wp:term":[{"taxonomy":"product_brand","embeddable":true,"href":"https:\/\/medsbase.com\/ro\/wp-json\/wp\/v2\/product_brand?post=53110"},{"taxonomy":"product_cat","embeddable":true,"href":"https:\/\/medsbase.com\/ro\/wp-json\/wp\/v2\/product_cat?post=53110"},{"taxonomy":"product_tag","embeddable":true,"href":"https:\/\/medsbase.com\/ro\/wp-json\/wp\/v2\/product_tag?post=53110"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}